Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
Objective: This study compared the impact of 3 eicosapentaenoic acid (EPA) doses versus placebo on inflammatory biomarkers and depressive symptoms. Methods: Sixty-one unmedicated adults (75% female; 45.5 ± 13.8 years) with DSM-5 major depressive disorder (MDD), body mass index > 25 kg/m2, and plasma high-sensitivity C-reactive protein (hs-CRP) ≥ 3.0 mg/L were randomly assigned to receive EPA 1 g/d, 2 g/d, or 4 g/d or placebo for 12 weeks. Prespecified endpoints were a ≥ 0.40 effect size decrease in plasma interleukin (IL)-6, peripheral blood mononuclear cell (PBMC) cytokines, and lipopolysaccharide-stimulated tumor necrosis factor (TNF) production. Response was defined as a ≥ 50% decrease of Inventory of Depressive Symptomatology, Clinician-Rated version (IDS-C30) scores. We compared outcomes for the 3 EPA doses versus placebo. Results: In 45 completers, only median PBMC TNF decreased at 2 g/d EPA. No EPA dose produced a ≥ 0.35 effect size reduction in plasma IL-6 or mitogen-stimulated TNF. Response rates for EPA 4 g/d were 64%, versus 40% for placebo (odds ratio = 2.63; Cohen d = 0.53), 38% for EPA 1 g/d, and 36% for EPA 2 g/d (all P > .05). EPA 4 g/d showed a significant correlation between percent decrease in plasma hs-CRP and IDS-C30 symptom reduction at 12 weeks (Spearman ρ = 0.691, P = .019). Conclusions: EPA 4 g/d demonstrated a medium effect size for response rates versus placebo. This dose may alleviate MDD in overweight individuals with elevated inflammatory markers, and change in hs-CRP may be correlated with clinical response. Trial Registration: ClinicalTrials.gov identifier: NCT02553915
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A dose finding study comparing 1 g, 2 g, or 4 g of omega-fatty acid capsules with a 4:1 ratio of EPA:DPA reported that high-doses (4 g/per day) were required for antidepressant efficacy in overweight or obese patients with inflammation (156).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [156]
Citations
Cites
Still being checked.
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“A dose finding study comparing 1 g, 2 g, or 4 g of omega-fatty acid capsules with a 4:1 ratio of EPA:DPA reported that high-doses (4 g/per day) were required for antidepressant efficacy in overweight or obese patients with inflammation (156).”
BackgroundUnsaturated Fatty Acids and Their Immunomodulatory Properties
Coniglio, S. J., Shumskaya, M. A., & Vassiliou, E. K. (2023) · Biology · doi:10.3390/biology12020279 · Cited by 200
Kalogerakou, T., & Αντωνιάδου, Μ. (2024) · Antioxidants · doi:10.3390/antiox13121508 · Cited by 124
Omega-3 Polyunsaturated Fatty Acids in Depression
Serefko, A., Jach, M. E., Pietraszuk, M., Świąder, M., Świąder, K., & Szopa, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168675 · Cited by 87
Du, Y., Dou, Y., Wang, M., Wang, Y., Yan, Y., Fan, H., Fan, N., Yang, X., & Ma, X. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1407529 · Cited by 65
The metabolome-wide signature of major depressive disorder
Jansen, R., Milaneschi, Y., Schranner, D., Kastenmüller, G., Arnold, M., Han, X., Dunlop, B. W., Rush, A. J., Kaddurah‐Daouk, R., & Penninx, B. W. J. H. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02613-6 · Cited by 62
Self-citationThe Effects and Mechanisms of n-3 and n-6 Polyunsaturated Fatty Acids in the Central Nervous System
Tian, J., Zhang, Y., & Zhao, X. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01543-3 · Cited by 56
Applications of Perilla frutescens Extracts in Clinical Practice
Adam, G., Robu, S., Flutur, M.-M., Cioancă, O., Vasilache, I.-A., Adam, A.-M., Mircea, C., Nechita, A., Harabor, V. R., Hărăbor, A., et al. (2023) · Antioxidants · doi:10.3390/antiox12030727 · Cited by 54
Lamon‐Fava, S., Liu, M., Dunlop, B. W., Kinkead, B. L., Schettler, P. J., Felger, J. C., Ziegler, T. R., D, M. F. M., Mischoulon, D., & Rapaport, M. H. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01527-7 · Cited by 39
Self-citationPrebiotics for depression: how does the gut microbiota play a role?
Yang, Y., Bi, Z., Zhang, S., Si, L., Liu, X., & Li, F. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1206468 · Cited by 39
Sublette, M. E., Daray, F. M., Ganança, L., & Shaikh, S. R. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02322-6 · Cited by 37
Nutraceuticals in Psychiatric Disorders: A Systematic Review
Bozzatello, P., Novelli, R., Montemagni, C., Rocca, P., & Bellino, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094824 · Cited by 36
Intestinal Barrier, Immunity and Microbiome: Partners in the Depression Crime
Medina-Rodriguez, E. M., Martínez-Raga, J., & Sanz, Y. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001202 · Cited by 34
Omega-3 fatty acids for inflamed depression – A match/mismatch study
Suneson, K., Veibäck, G. S., Lindahl, J., Tjernberg, J., Ståhl, D., Ventorp, S., Ängeby, F., Lundblad, K., Wolkowitz, O. M., & Lindqvist, D. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.02.029 · Cited by 33
Omega-3 polyunsaturated fatty acids in depression: insights from recent clinical trials
Dyall, S. C., Malau, I. A., & Su, K. (2024) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001077 · Cited by 22
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 24
Self-citationWu, S., Chen, W.-J., Chang, J. P., Guu, T., Hsin, M.-C., Huang, C., Mischoulon, D., Capuron, L., & Su, K. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13061003 · Cited by 21
Self-citationWu, S., Yang, K.-J., Liu, W., Malau, I. A., Zailani, H., Chang, C., Huang, S., Chang, J. P., Chiu, W., & Su, K. (2024) · Nutrients · doi:10.3390/nu16213688 · Cited by 20
Giollabhui, N. M., Mischoulon, D., Dunlop, B. W., Kinkead, B. L., Schettler, P. J., Liu, R. T., Okereke, O. I., Lamon‐Fava, S., Fava, M., & Rapaport, M. H. (2023) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2023.100666 · Cited by 19
Self-citationXia, J., Chen, M., Shao, H., Chen, H., Zhu, S., Zhao, M., Luo, W., Yang, J., & Wu, S. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2812356 · Cited by 19
Mandal, G., Alboni, S., Cattane, N., Marizzoni, M., Saleri, S., Arslanovski, N., Mariani, N., Kirkpatrick, M., Cattaneo, A., Pariante, C. M., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03119-5 · Cited by 16
Cillis, F. D., Begni, V., Genini, P., Leo, D., Riva, M. A., & Cattaneo, A. (2025) · Nutrients · doi:10.3390/nu17213426 · Cited by 15
Chang, J. P., Iqbal, A. Z., Do, Q. L., Yaseen, M., Wu, S., Malau, I. A., Zailani, H., & Su, K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107857 · Cited by 14
The United States index of socioeconomic deprivation for individuals (USiDep)
Dunlop, B. W., Rakofsky, J. J., Mischoulon, D., Mayberg, H. S., Kinkead, B. L., Nierenberg, A. A., Ziegler, T. R., D, M. F. M., & Rapaport, M. H. (2022) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2022.100091 · Cited by 11
Self-citationMicrobiome: A Key Regulator of Body-Brain Interactions
O’Riordan, K. J., Aburto, M. R., Nagpal, J. K., Clarke, G. A., & Cryan, J. F. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-89525-8_6 · Cited by 10
Wang, Z., Yang, Y., Tang, F., & Wu, M. (2024) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2024.102615 · Cited by 9
Panţuroiu, M., Gălățanu, M. L., Cristache, R. E., & Truţǎ, E. (2025) · Journal of Science and Arts · doi:10.46939/j.sci.arts-25.2-b01 · Cited by 8
Targeting Divergent Pathways in the Nutritional Management of Depression
Tobin, D., Vuckovic, A., & Sarris, J. J. (2024) · Nutrients · doi:10.3390/nu16162806 · Cited by 8
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
ω-3 Fatty Acids in Pediatric Major Depressive Disorder: A Randomized Clinical Trial
Berger, G. E., Häberling, I. S., Emery, S., Albermann, M., Baumgartner, N., Nalani, K., Strumberger, M. A., Wöckel, L., Erb, S., Bachmann, S., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.48703 · Cited by 7
Personalized Eicosapentaenoic Acid Therapy for Clinical Depression
Zailani, H., Mischoulon, D., Dyall, S. C., Pariante, C. M., & Su, K. (2025) · Psychiatric Annals · doi:10.3928/00485713-20250114-03 · Cited by 6
Self-citationCheng, Y.-C., Chen, W.-Y., Lin, C., Lee, S.-H., Chiu, C.-C., & Kuo, P.-H. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.129 · Cited by 5
Omega-3 Supplementation Reduces Schizotypal Personality in Children: A Randomized Controlled Trial
Raine, A., Gur, R. C., Gur, R. E., Richmond, T. S., Hibbeln, J. R., & Liu, J. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae009 · Cited by 5
Zhang, M., Liu, C., Zhang, X., Zhao, L., Li, Y., & Su, M. (2024) · Actas Españolas de Psiquiatría · doi:10.62641/aep.v52i4.1654 · Cited by 5
Epigenetic, neuroplasticity, and adrenergic targets associated with major depression in immune cells
Cortés-Erice, M., Garayo, A., Fernández-Ovejero, R., Aubá, E., Lizaso, S., Aldaz, P., Bes‐Rastrollo, M., Gil, J. L., Barrado, L., Ortuño, F., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-36954-9 · Cited by 4
Shen, T., Jiang, L., Zhang, Q., Xv, M., & Wu, S. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04427-z · Cited by 4
Chang, J. P., Wu, S., Capuron, L., & Su, K. (2025) · Psychiatric Annals · doi:10.3928/00485713-20250113-01 · Cited by 4
Pinto, B., Domingues, I., Ferreira, H. B., Melo, T., & Domingues, M. R. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.08.003 · Cited by 4
Nutraceuticals in the Treatment of Major Depressive Disorder
Davis, A., Pence, J., & Bloomer, R. J. (2025) · Nutraceuticals · doi:10.3390/nutraceuticals5030027 · Cited by 3
Azhar, W. F., Qadhi, A., Abusudah, W. F., Ghabashi, M. A., Aljaadi, A. M., Alyamani, R. A., Awlya, O. F., Almohmadi, N. H., Alsemeri, A., Felemban, A. S., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121055 · Cited by 3
RetractedLindahl, J., Veibäck, G. S., Suneson, K., Blanking, W., Tjernberg, J., Ståhl, D., Wiman, Å., Ventorp, F., Erhardt, S., & Lindqvist, D. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101221 · Cited by 3
Chen, M., Huang, H., Huang, X., Liu, J., Liu, Y., Yu, Q., Ruan, H., Nguyen, S. V., Lu, X., Zheng, S., et al. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106589 · Cited by 3
Li, Z.-K., Gao, Y., Li, H.-N., Peng, Y.-X., Qiao, J.-J., Liu, S., & Yan, X. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1789372 · Cited by 3
Kulikova, A., Palka, J. M., Enkevort, E. A. V., DeFina, L. F., Ly, H., Sunderajan, P., Willis, B. L., Barlow, C. E., & Brown, E. S. (2023) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2023.111181 · Cited by 3
Li, M., & Li, F. (2025) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000011997 · Cited by 3
A lasma rotein rofile of ntidepressant esponse to omega-3 atty cids
Lindahl, J., Stiernborg, M., Ventorp, F., Suneson, K., Veibäck, G. S., Tjernberg, J., Ståhl, D., Hjärn, M., Lavebratt, C., & Lindqvist, D. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111481 · Cited by 2
Sex differences in nutritional psychiatry: Are omega-3 fatty acids more effective in women with MDD?
Smolensky, I. V., Inta, D., Su, K. P., & Marx, W. (2025) · Nutritional Psychiatry · doi:10.1016/j.nupsyc.2025.100003 · Cited by 2
Yin, J., Jiang, L., Zhang, H., Zhang, J., Zhang, J., Yao, N., Shi, Y., & Han, Z. (2025) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2025.112131 · Cited by 1
Fornaro, M., Lorenzo, C. D., Núñez, N. A., Miola, A., Calati, R., Carvalho, A. F., Steardo, L., Stubbs, B., Mischoulon, D., Correll, C. U., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03759-1 · Cited by 1
Self-citationKlettke, E. E., Holmes, M. D., Meyer, T. D., & Jones, G. H. (2023) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2023.100112 · Cited by 1
Nutrition and lifestyle medicine for neurodevelopmental and psychiatric disorders
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4378-8
Psychological disorders and omega-3s
Lembke, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-29114-2.00018-0
Impacto do ômega 3 no tratamento do transtorno depressivo: uma revisão da literatura
Ribeiro, C. K., Castro, S. C. C., Fabris, R. C., & Santini, A. D. R. (2024) · Congresso Brasileiro de Medicina do Estilo de Vida · doi:10.61661/congresso.cbmev.7.2024.112
Ômega-3 para Transtorno Depressivo: as evidências até o momento
Ribeiro, C. K., & Castro, S. C. C. (2025) · Brazilian Journal of Health Review · doi:10.34119/bjhrv8n5-183
Selected Lipidome Components and Their Association with Perinatal Depression
Ładno, D., Nowak, B., Palka, A., Strzelecki, D., & Gawlik-Kotelnicka, O. (2025) · Nutrients · doi:10.3390/nu17223590
Metabolic syndrome, depression, and omega-3 polyunsaturated fatty acids
Serhiyenko, A. A., Hotsko, M. E., Oliinyk, A. Y., & Serhiyenko, V. A. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.21.8.2025.1662
Tyagi, N., & Bisht, D. (2026) · Springer eBooks · doi:10.1007/978-981-95-4169-0_15
Oméga 3 et troubles de l'humeur : mécanismes d'actions neuroprotecteurs
Martinat, M. (2022) · theses.fr (ABES) · doi:10.70675/6f114f20z6c83z41a1zaa52zb4bae73f6832
Kowalczyk, M., Aebisher, D., Szpara, J., Czech, S., Kowalczyk, E., Majsterek, I., Bartusik‐Aebisher, D., & Henrykowska, G. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114705
Pan, L., 卢亚飞, Wang, Y., He, M., He, C., Li, J., Zhang, L., Zhang, T., Su, C., Gao, T., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6951842
Neuroinflammation in Major Depressive Disorder: Mechanisms, Biomarkers, and Therapeutic Implications
Włoszek, E., Mikołajek, B., Godlewska, A., Kocik, A., Wiak, B., Wywiał, A., Spaczyńska, K., Kropiwnicka, A., Racki, E., Motaouakkil, Y., et al. (2026) · African Journal of Biomedical Research · doi:10.69980/qy1sgw94
Okuhira, K., Takahashi, S., Funai, S., Uenishi, Y., Ishida, T., & Kimoto, S. (2026) · Journal of Ect · doi:10.1097/yct.0000000000001343
Chapter 10. Diet Interventions
(2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550930.lg10
Nyland, J. J. A. O. L., Silva, A. E. A., Vianna, I. D. M., Shikanai, J. D. S., & Rocha, J. S. D. S. (2026) · Revista Científica Ipedss · doi:10.55703/27644006060403
The Synergistic Effects of Nutrition and Physical Activity on Cognitive Function and Mental Health
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8998-4
Metadata
- Authors
- Mischoulon, D., Dunlop, B. W., Kinkead, B., Schettler, P. J., Lamon-Fava, S., Rakofsky, J. J., Nierenberg, A. A., Clain, A. J., Crowe, T. M., Wong, A., Felger, J. C., Sangermano, L., Ziegler, T. R., Cusin, C., Fisher, L. B., Fava, M., & Rapaport, M. H.
- Affiliations
- Massachusetts General Hospital (US)
- Emory University (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2022-08-22
- Volume
- 83
- Issue
- 5
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W4292361112
- Cited by
- 56
- References
- 0
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 15 · 2023: 11 · 2022: 1
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- Funders
- National Center for Complementary and Integrative Health (UG3AT008857)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- eicosapentaenoic acid, omega-3 fatty acids, major depressive disorder, inflammation, C-reactive protein, interleukin-6, TNF-α, peripheral blood mononuclear cells, dose-response relationship, overweight, inflammatory markers, depressive symptoms
- MeSH terms
- Adult, C-Reactive Protein, Major Depressive Disorder, Docosahexaenoic Acids, Double-Blind Method, Female, Humans, Inflammation, Leukocytes, Mononuclear, Male, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Interleukin-6, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.